Preliminary results of a phase II trial of dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinorna
2005-01-01 Reni, M; Cereda, S; Dell'Oro, S; Passoni, P; Bonetto, E; Vigano, M; Balzano, G; Zerbi, A; Staudacher, C; Di Carlo, V
The Oncogene MYC Triggers Replicative Stress and DNA Damage In Multiple Myeloma
2013-01-01 Cottini, F; Hideshima, T; Tonon, G; Anderson, Kc
PEF-G (cisplatin, epirubicin, 5-fluorouracil continuous infusion, gemcitabine): a new combination in advanced pancreatic adenocarcinoma: phase II study
1999-01-01 Villa, E; Reni, M
A next generation sequencing study in Italian multiplex families with multiple sclerosis
2016-01-01 Guaschino, C; Zauli, A; Esposito, F; Sorosina, M; Mascia, E; Osiceanu, Am; Santoro, S; Biancolini, D; Bonfiglio, S; Lazarevic, D; Tonon, G; Martinelli, V; Comi, G; Boneschi, Fm
Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer
2007-01-01 Cereda, S; Mazza, E; Vigano, M; Passoni, P; Balzano, G; Zerbi, A; Staudacher, C; di Carlo, V; Reni, M
Targeting Mcl-1 for multiple myeloma (MM) therapy: Drug-induced generation of Mcl-1 fragment Mcl-1128-350 triggers MM cell death via c-Jun upregulation
2013-01-01 Fan, F; Tonon, G; Bashari, Hm; Vallet, S; Antonini, E; Goldschmidt, H; Schulze-Bergkamen, H; Opferman, J; Settler, M; Anderson, Kc; Jager, D; Podar, K
Final results of a phase III trial of gemcitabine (G) versus PEFG regimen in stage IVA or metastatic pancreatic adenocarcinoma (PA)
2004-01-01 Reni, M; Cordio, S; Passardi, A; Panucci, Mg; Passoni, P; Oliani, C; Luppi, G; Galli, L; Nicoletti, R; Villa, E
Targeting PKC: A Novel Role for Beta-catenin in ER Stress and Apoptotic Signaling
2008-01-01 Raab, Ms; Breitkreutz, I; Tonon, G; Zhang, J; Fruehauf, J; Lin, Bk; Chauhan, D; Hideshima, T; Munshi, N; Anderson, Kc; Podar, K
CS1, a new surface target on multiple myeloma (MM) cells, protects myeloma cells from apoptosis via-regulation of ERKI/2, AKT and STAT3 signaling cascades
2007-01-01 Tai, Yt; Tonon, G; Leiba, M; Li, Xf; Burger, P; Song, W; Podar, K; Munshi, N; Anderson, Kc
Impact on outcome of consolidation radiotherapy (RT) in stage I-II diffuse large cell lymphoma (DLCL) of Waldeyers’ ring (WR)
1998-01-01 Ferreri, Ajm; Dell’Oro, S; Meazza, M; Reni, M; Ceresoli, Gl; Ponzoni, M; Villa, E
MUTATIONAL SPECTRUM OF BRAF, NRAS AND KRAS IN MULTIPLE MYELOMA
2015-01-01 Lionetti, M; Barbieri, M; Todoerti, K; Agnelli, L; Marzorati, S; Fabris, S; Ciceri, G; Galletti, S; Milesi, G; Manzoni, M; Mazzoni, M; Greco, A; Tonon, G; Musto, P; Baldini, L; Neri, A
Definitive results of a phase II trial of PEF-G (cisplatin, epirubicin, 5-fluorouracil continous infusion, gemcitabine) in stage IV pancreatic adenocarcinoma
2000-01-01 Reni, M; Passoni, P; Panucci, Mg; Villa, E
Lentiviral Vector-Based Insertional Mutagenesis Identifies New Oncogenes and Molecular Networks That Control Hepatocyte Transformation and Metabolism
2013-01-01 Ranzani, ; Marco, ; Cesana, ; Daniela, ; Bartholomae, ; Cynthia, ; Sanvito, ; Francesca, ; Annunziato, ; Stefano, ; Riba, ; Michela, ; Benedicenti, ; Fabrizio, ; Gallina, ; Pierangela, ; Doglioni, ; Claudio, ; Von, Kalle; Christof, ; Kim, ; Yoon, Jun; Stupka, ; Elia, ; Schmidt, ; Manfred, ; Tonon, G; Naldini, ; Luigi, ; Montini, ; Eugenio,
Primary non-Hodgkin's lymphoma of the bone (PLB): Management of 21 cases
1995-01-01 Ferreri, Ajm; Reni, M; Ceresoli, G; Cozzarini, C; Villa, E
KMD6A/UTX loss enhances the malignant phenotype of multiple myeloma and sensitizes cells to EZH2 inhibition
2017-01-01 Dupere-Richer, D; Ezponda, T; Will, C; Small, Ec; Varghese, N; Tej, P; Huang, Xx; Zheng, Yp; Tonon, G; Kelleher, N; Keats, J; Licht, Jd
Quality of life outcome in advanced pancreatic adenocarcinoma: results from a phase III trial
2004-01-01 Reni, M; Bonetto, E; Cordio, S; Passoni, P; Milandri, C; Dell'Oro, S; Galli, L; Bordonaro, R; Villa, E; Johnson, Cd
Targeting Replicative Stress to Treat Hematological Disorders
2015-01-01 Cottini, ; Francesca, ; Tonon, G; Hideshima, ; Teru, ; Richardson, ; Paul, G.; Anderson, ; Kenneth, C.
Prognostic scoring system for Primary Central Nervous System Lymphomas: the IELSG proposal
2001-01-01 Ferreri, Ajm; Blay, J-Y; Calderoni, A; Ambrosetti, A; Tirelli, U; Cortelazzo, S; Gubkin, A; Zucca, E; Gomez, H; Orvieto, E; Borish, B; Berger, F; Jouvet, A; Tingueli, M; Chassagne, C; Ponzoni, M; Reni, M
Loss of the histone demethylase UTX alters the gene expression prolife and contributes to the malignant phenotype of multiple myeloma cells
2015-01-01 Ezponda, ; Teresa, ; Popovic, ; Relja, ; Zheng, ; Yupeng, ; Nabet, ; Behnam, ; Will, ; Christine, ; Small, ; Eliza, ; Occhionorelli, ; Manuela, ; Tonon, G; Keats, ; Jonathan, ; Kelleher, ; Neil, ; Licht, ; Jonathan, D.
A MULTICENTER RETROSPECTIVE STUDY OF CHEMOTHERAPY IN ADULTS WITH EPENDYMOMA. GICNO (GRUPPO ITALIANO COOPERATIVO NEURO-ONCOLOGIA)
2004-01-01 Tosoni, A; Cavallo, G; Reni, M; Ermani, M; Nicolardi, L; Longhini, M; Franceschi, E; Scopece, L; Mazza, E; Brandes, Aa
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Preliminary results of a phase II trial of dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinorna | 1-gen-2005 | Reni, M; Cereda, S; Dell'Oro, S; Passoni, P; Bonetto, E; Vigano, M; Balzano, G; Zerbi, A; Staudacher, C; Di Carlo, V | |
| The Oncogene MYC Triggers Replicative Stress and DNA Damage In Multiple Myeloma | 1-gen-2013 | Cottini, F; Hideshima, T; Tonon, G; Anderson, Kc | |
| PEF-G (cisplatin, epirubicin, 5-fluorouracil continuous infusion, gemcitabine): a new combination in advanced pancreatic adenocarcinoma: phase II study | 1-gen-1999 | Villa, E; Reni, M | |
| A next generation sequencing study in Italian multiplex families with multiple sclerosis | 1-gen-2016 | Guaschino, C; Zauli, A; Esposito, F; Sorosina, M; Mascia, E; Osiceanu, Am; Santoro, S; Biancolini, D; Bonfiglio, S; Lazarevic, D; Tonon, G; Martinelli, V; Comi, G; Boneschi, Fm | |
| Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer | 1-gen-2007 | Cereda, S; Mazza, E; Vigano, M; Passoni, P; Balzano, G; Zerbi, A; Staudacher, C; di Carlo, V; Reni, M | |
| Targeting Mcl-1 for multiple myeloma (MM) therapy: Drug-induced generation of Mcl-1 fragment Mcl-1128-350 triggers MM cell death via c-Jun upregulation | 1-gen-2013 | Fan, F; Tonon, G; Bashari, Hm; Vallet, S; Antonini, E; Goldschmidt, H; Schulze-Bergkamen, H; Opferman, J; Settler, M; Anderson, Kc; Jager, D; Podar, K | |
| Final results of a phase III trial of gemcitabine (G) versus PEFG regimen in stage IVA or metastatic pancreatic adenocarcinoma (PA) | 1-gen-2004 | Reni, M; Cordio, S; Passardi, A; Panucci, Mg; Passoni, P; Oliani, C; Luppi, G; Galli, L; Nicoletti, R; Villa, E | |
| Targeting PKC: A Novel Role for Beta-catenin in ER Stress and Apoptotic Signaling | 1-gen-2008 | Raab, Ms; Breitkreutz, I; Tonon, G; Zhang, J; Fruehauf, J; Lin, Bk; Chauhan, D; Hideshima, T; Munshi, N; Anderson, Kc; Podar, K | |
| CS1, a new surface target on multiple myeloma (MM) cells, protects myeloma cells from apoptosis via-regulation of ERKI/2, AKT and STAT3 signaling cascades | 1-gen-2007 | Tai, Yt; Tonon, G; Leiba, M; Li, Xf; Burger, P; Song, W; Podar, K; Munshi, N; Anderson, Kc | |
| Impact on outcome of consolidation radiotherapy (RT) in stage I-II diffuse large cell lymphoma (DLCL) of Waldeyers’ ring (WR) | 1-gen-1998 | Ferreri, Ajm; Dell’Oro, S; Meazza, M; Reni, M; Ceresoli, Gl; Ponzoni, M; Villa, E | |
| MUTATIONAL SPECTRUM OF BRAF, NRAS AND KRAS IN MULTIPLE MYELOMA | 1-gen-2015 | Lionetti, M; Barbieri, M; Todoerti, K; Agnelli, L; Marzorati, S; Fabris, S; Ciceri, G; Galletti, S; Milesi, G; Manzoni, M; Mazzoni, M; Greco, A; Tonon, G; Musto, P; Baldini, L; Neri, A | |
| Definitive results of a phase II trial of PEF-G (cisplatin, epirubicin, 5-fluorouracil continous infusion, gemcitabine) in stage IV pancreatic adenocarcinoma | 1-gen-2000 | Reni, M; Passoni, P; Panucci, Mg; Villa, E | |
| Lentiviral Vector-Based Insertional Mutagenesis Identifies New Oncogenes and Molecular Networks That Control Hepatocyte Transformation and Metabolism | 1-gen-2013 | Ranzani, ; Marco, ; Cesana, ; Daniela, ; Bartholomae, ; Cynthia, ; Sanvito, ; Francesca, ; Annunziato, ; Stefano, ; Riba, ; Michela, ; Benedicenti, ; Fabrizio, ; Gallina, ; Pierangela, ; Doglioni, ; Claudio, ; Von, Kalle; Christof, ; Kim, ; Yoon, Jun; Stupka, ; Elia, ; Schmidt, ; Manfred, ; Tonon, G; Naldini, ; Luigi, ; Montini, ; Eugenio, | |
| Primary non-Hodgkin's lymphoma of the bone (PLB): Management of 21 cases | 1-gen-1995 | Ferreri, Ajm; Reni, M; Ceresoli, G; Cozzarini, C; Villa, E | |
| KMD6A/UTX loss enhances the malignant phenotype of multiple myeloma and sensitizes cells to EZH2 inhibition | 1-gen-2017 | Dupere-Richer, D; Ezponda, T; Will, C; Small, Ec; Varghese, N; Tej, P; Huang, Xx; Zheng, Yp; Tonon, G; Kelleher, N; Keats, J; Licht, Jd | |
| Quality of life outcome in advanced pancreatic adenocarcinoma: results from a phase III trial | 1-gen-2004 | Reni, M; Bonetto, E; Cordio, S; Passoni, P; Milandri, C; Dell'Oro, S; Galli, L; Bordonaro, R; Villa, E; Johnson, Cd | |
| Targeting Replicative Stress to Treat Hematological Disorders | 1-gen-2015 | Cottini, ; Francesca, ; Tonon, G; Hideshima, ; Teru, ; Richardson, ; Paul, G.; Anderson, ; Kenneth, C. | |
| Prognostic scoring system for Primary Central Nervous System Lymphomas: the IELSG proposal | 1-gen-2001 | Ferreri, Ajm; Blay, J-Y; Calderoni, A; Ambrosetti, A; Tirelli, U; Cortelazzo, S; Gubkin, A; Zucca, E; Gomez, H; Orvieto, E; Borish, B; Berger, F; Jouvet, A; Tingueli, M; Chassagne, C; Ponzoni, M; Reni, M | |
| Loss of the histone demethylase UTX alters the gene expression prolife and contributes to the malignant phenotype of multiple myeloma cells | 1-gen-2015 | Ezponda, ; Teresa, ; Popovic, ; Relja, ; Zheng, ; Yupeng, ; Nabet, ; Behnam, ; Will, ; Christine, ; Small, ; Eliza, ; Occhionorelli, ; Manuela, ; Tonon, G; Keats, ; Jonathan, ; Kelleher, ; Neil, ; Licht, ; Jonathan, D. | |
| A MULTICENTER RETROSPECTIVE STUDY OF CHEMOTHERAPY IN ADULTS WITH EPENDYMOMA. GICNO (GRUPPO ITALIANO COOPERATIVO NEURO-ONCOLOGIA) | 1-gen-2004 | Tosoni, A; Cavallo, G; Reni, M; Ermani, M; Nicolardi, L; Longhini, M; Franceschi, E; Scopece, L; Mazza, E; Brandes, Aa |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 4 Contributo in Atti di Convegno ...3017
Data di pubblicazione
- In corso di stampa1
- 2020 - 2025370
- 2010 - 2019987
- 2000 - 20091246
- 1990 - 1999399
- 1985 - 198914
Editore
- SAGE PUBLICATIONS LTD152
- LIPPINCOTT WILLIAMS & WILKINS85
- WILEY49
- ELSEVIER30
- Edizioni Minerva Medica22
- OXFORD UNIV PRESS18
- ELSEVIER SCIENCE INC15
- CELL PRESS13
- Società Italiana di Igiene, Medic...11
- BMJ PUBLISHING GROUP10
Rivista
- MULTIPLE SCLEROSIS157
- BLOOD77
- NEUROLOGY76
- INVESTIGATIVE OPHTHALMOLOGY & VIS...65
- EUROPEAN JOURNAL OF NEUROLOGY46
- ANNALS OF ONCOLOGY44
- ANNALS OF THE RHEUMATIC DISEASES27
- GASTROENTEROLOGY26
- HAEMATOLOGICA22
- MOLECULAR THERAPY21
Serie
- IFMBE PROCEEDINGS1
- INTERNATIONAL CONFERENCE ON PATTE...1
- PROCEEDINGS INTERNATIONAL SYMPOSI...1
- RADIOTHERAPY AND ONCOLOGY1
Keyword
- FA16
- ICG16
- MRI16
- OCT16
- RTA16
- SLO16
- Systemic Sclerosis14
- rehabilitation7
- ultrasound)7
- Keywords: imaging methods (CT6
Lingua
- eng1256
- ita450
- fre23
- und21
- ger1
- jpn1
- por1
Accesso al fulltext
- no fulltext2961
- reserved34
- open22